Advertisement

Anti-VEGF Therapy: Basics and Substances

  • S. GrisantiEmail author
  • J. Lüke
  • S. Peters
Chapter

Abstract

VEGF refers to several factors and isoforms that bind to distinguished receptors, which initiate different pathways and modulate a multitude of complex mechanisms including neovascularization.

Keywords

Vascular Endothelial Growth Factor Vascular Endothelial Growth Factor Receptor Diabetic Macular Edema Vascular Endothelial Growth Factor Signaling Pigment Epithelium Derive Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 27: 372–390PubMedCrossRefGoogle Scholar
  2. 2.
    Takahashi H, Shibuya M (2005) The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci 109:227–241PubMedCrossRefGoogle Scholar
  3. 3.
    Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, Claesson-Welsh L, Janjić N (1998) 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273:20556–20567PubMedCrossRefGoogle Scholar
  4. 4.
    Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME (1999) Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 35:533–542PubMedCrossRefGoogle Scholar
  5. 5.
    Tucker CE, Chen LS, Judkins MB, Farmer JA, Gill SC, Drolet DW (1999) Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr B Biomed Sci Appl 732:203–212PubMedCrossRefGoogle Scholar
  6. 6.
    Drolet DW, Nelson J, Tucker CE, Zack PM, Nixon K, Bolin R, Judkins MB, Farmer JA, Wolf JL, Gill SC, Bendele RA (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17:1503–1510PubMedCrossRefGoogle Scholar
  7. 7.
    Ishida S, Usui T, Yamashiro K, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP (2003) VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44:2155–2162PubMedCrossRefGoogle Scholar
  8. 8.
    Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP (2004) VEGF 164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 45:368–374PubMedCrossRefGoogle Scholar
  9. 9.
    Ferrara N, D’Amico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26:850–870CrossRefGoogle Scholar
  10. 10.
    Bartz-Schmidt KU, Ziemssen F (2008) Intravitreallye pharmakotherapie. Schattauer, Stuttgart/NewYorkGoogle Scholar
  11. 11.
    Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA, CLEAR-AMD 1 Study Group (2006) A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113:1522.e1–1522.e14CrossRefGoogle Scholar
  12. 12.
    Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, Pyles EA, Xu X, Daly TJ, Young MR, Fandl JP, Lee F, Carver S, McNay J, Bailey K, Ramakanth S, Hutabarat R, Huang TT, Radziejewski C, Yancopoulos GD, Stahl N (2003) Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 9:47–52PubMedCrossRefGoogle Scholar
  13. 13.
    Gebauer M, Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 3:245–255CrossRefGoogle Scholar
  14. 14.
    Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, Wadsworth SC, Scaria A (2009) Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16:10–16PubMedCrossRefGoogle Scholar
  15. 15.
    Kyowa Hakko Kogyo KK (2003) VEGF receptor Flt-1 monoclonal antibody. US6617160, 9 Sep 2003Google Scholar
  16. 16.
    Kwak N, Okamoto N, Wood JM, Campochiaro PA (2000) VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41:3158–3164PubMedGoogle Scholar
  17. 17.
    Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E, Frank RN, Saperstein DA, Gupta A, Stout JT, Macko J, DiBartolomeo R, Wei LL (2006) Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17:167–176PubMedCrossRefGoogle Scholar
  18. 18.
    Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, Penn M, Chen CT, Mori K, Melia M, Phipps S, Moffat D, Brazzell K, Liau G, Dixon KH, Campochiaro PA (2001) Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 159:313–3201PubMedCrossRefGoogle Scholar
  19. 19.
    Strieth S, Nussbaum CF, Eichhorn ME, Fuhrmann M, Teifel M, Michaelis U, Berghaus A, Dellian M (2008) Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 122:452–460PubMedCrossRefGoogle Scholar
  20. 20.
    Danis R, Criswell M, Orge F, Wancewicz E, Stecker K, Henry S, Monia BD (2003) Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr Eye Res 26:45–54PubMedCrossRefGoogle Scholar
  21. 21.
    Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210–216PubMedGoogle Scholar
  22. 22.
    The CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 364:1897–1908PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of OphthalmologyThe University of LuebeckLuebeckGermany

Personalised recommendations